The company said it has decided to stop distributing its once-daily basal insulin Tresiba (insulin degludec) in Germany - Europe's largest pharmaceutical market - in the wake of a "negative ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that Novo Nordisk’s long-acting insulin, Tresiba (degludec), is approved for use in Europe.

Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026.

“Without insulin, I die.” Novo Nordisk manufactures insulin products like NovoLog, Tresiba, Fiasp and Novolin. Novo Nordisk will also provide free insulin to qualifying patients below a ...

The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s NVO Tresiba (insulin degludec) for 78 weeks in T2D patients who have switched from daily basal insulin injections.

and now next-generation insulin analogs (Tresiba, Fiasp), which offer improved efficacy, safety, and convenience for patients. Tresiba also appears to offer greater dosing flexibility and less ...

Premix insulin (Ryzodeg and NovoMix) revenues grew 33% year over year. Sales of long-acting insulins (Tresiba, Xultophy, Levemir and Awiqli) jumped 40% in the fourth quarter. Ozempic, which has ...